logo
Share SHARE
FONT-SIZE Plus   Neg

Lorus Therapeutics Receives Patent Approval For Anticancer Drug LOR-253

Lorus Therapeutics Inc. (LOR.TO) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.

The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.

The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.

LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A Brazilian judge has ordered all wireless phone carriers in the country to block WhatsApp after the Facebook-owned messaging service failed to comply with an order asking to turn over data related to a criminal investigation. According to reports, the app, which is used by over 100 million Brazilians,... Amazon.com Inc. intends to bring its free same-day delivery to the Bronx and Chicago's South Side areas. The online retailer's plans comes after severe criticism were raised that the company unfairly left out some predominantly black and Hispanic areas from its Prime service. An analysis done by... Sprint Corp., the third largest U.S. wireless carrier, on Tuesday reported a loss for the fourth quarter that widened from last year on one-time charges and lower revenues. The latest quarter's results include charges related to severance and lease exit costs, including the shutdown of legacy WiMAX service that will free up valuable spectrum and immediately lower network costs.
comments powered by Disqus
Follow RTT